ATE288502T1 - Gezieltes antikörper-verfahren - Google Patents

Gezieltes antikörper-verfahren

Info

Publication number
ATE288502T1
ATE288502T1 AT02788114T AT02788114T ATE288502T1 AT E288502 T1 ATE288502 T1 AT E288502T1 AT 02788114 T AT02788114 T AT 02788114T AT 02788114 T AT02788114 T AT 02788114T AT E288502 T1 ATE288502 T1 AT E288502T1
Authority
AT
Austria
Prior art keywords
methods
targeted antibody
vaccine
antibody process
vaccinating
Prior art date
Application number
AT02788114T
Other languages
English (en)
Inventor
James Peter Burnie
Ruth Christine Matthews
Gordon Patrick Rigg
Peter Williamson
Original Assignee
Neutec Pharma Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9927861&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE288502(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neutec Pharma Plc filed Critical Neutec Pharma Plc
Application granted granted Critical
Publication of ATE288502T1 publication Critical patent/ATE288502T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5052—Cells of the immune system involving B-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6818—Sequencing of polypeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT02788114T 2001-12-19 2002-12-16 Gezieltes antikörper-verfahren ATE288502T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0130267.8A GB0130267D0 (en) 2001-12-19 2001-12-19 Focussed antibody technology
PCT/GB2002/005690 WO2003052416A2 (en) 2001-12-19 2002-12-16 Focussed antibody technology

Publications (1)

Publication Number Publication Date
ATE288502T1 true ATE288502T1 (de) 2005-02-15

Family

ID=9927861

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02788114T ATE288502T1 (de) 2001-12-19 2002-12-16 Gezieltes antikörper-verfahren

Country Status (10)

Country Link
US (1) US20060233812A1 (de)
EP (1) EP1415002B1 (de)
AT (1) ATE288502T1 (de)
AU (1) AU2002352394A1 (de)
CA (1) CA2471570A1 (de)
DE (1) DE60202877T2 (de)
ES (1) ES2236605T3 (de)
GB (1) GB0130267D0 (de)
PT (1) PT1415002E (de)
WO (1) WO2003052416A2 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0309126D0 (en) * 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
GB0414886D0 (en) * 2004-07-02 2004-08-04 Neutec Pharma Plc Treatment of bacterial infections
EP2088432A1 (de) * 2008-02-11 2009-08-12 MorphoSys AG Verfahren zur Identifikation eines Antikörpers oder eines Targets
US8628927B2 (en) 2008-11-07 2014-01-14 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
US8691510B2 (en) 2008-11-07 2014-04-08 Sequenta, Inc. Sequence analysis of complex amplicons
US9528160B2 (en) 2008-11-07 2016-12-27 Adaptive Biotechnolgies Corp. Rare clonotypes and uses thereof
US9506119B2 (en) 2008-11-07 2016-11-29 Adaptive Biotechnologies Corp. Method of sequence determination using sequence tags
US8748103B2 (en) 2008-11-07 2014-06-10 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
EP2364368B1 (de) 2008-11-07 2014-01-15 Sequenta, Inc. Verfahren zur überwachung von krankheitszuständen mittels sequenzanalyse
US9365901B2 (en) 2008-11-07 2016-06-14 Adaptive Biotechnologies Corp. Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia
ES2726702T3 (es) 2009-01-15 2019-10-08 Adaptive Biotechnologies Corp Perfilado de la inmunidad adaptativa y métodos para la generación de anticuerpos monoclonales
US9079942B2 (en) * 2009-02-09 2015-07-14 Epitomics, Inc. CDR-anchored amplification method
CA2758356C (en) 2009-05-29 2016-07-26 Morphosys Ag A collection of vh and vl pairs having favourable biophysical properties and methods for its use
US20100317539A1 (en) * 2009-06-12 2010-12-16 Guo-Liang Yu Library of Engineered-Antibody Producing Cells
WO2010151416A1 (en) 2009-06-25 2010-12-29 Fred Hutchinson Cancer Research Center Method of measuring adaptive immunity
US8293483B2 (en) 2009-09-11 2012-10-23 Epitomics, Inc. Method for identifying lineage-related antibodies
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
SMT202600080T1 (it) 2010-02-08 2026-03-09 Regeneron Pharma Topo con catena leggera comune
CA2799746C (en) * 2010-05-17 2020-11-24 Sai Reddy Rapid isolation of monoclonal antibodies from animals
US8367586B2 (en) 2010-11-19 2013-02-05 Morphosys Ag Collection and methods for its use
JP6211931B2 (ja) 2011-03-09 2017-10-11 セル・シグナリング・テクノロジー・インコーポレイテツド モノクローナル抗体を作製するための方法および試薬
HUE047278T2 (hu) 2011-08-05 2020-04-28 Regeneron Pharma Humanizált univerzális könnyûláncú egerek
US10385475B2 (en) 2011-09-12 2019-08-20 Adaptive Biotechnologies Corp. Random array sequencing of low-complexity libraries
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
EP2768982A4 (de) 2011-10-21 2015-06-03 Adaptive Biotechnologies Corp Quantifizierung von adaptiven immunzellgenomen in einer komplexen mischung von zellen
EP2783214A2 (de) 2011-11-23 2014-10-01 The Board of Regents of The University of Texas System Proteomischer nachweis von antikörpern
US9824179B2 (en) 2011-12-09 2017-11-21 Adaptive Biotechnologies Corp. Diagnosis of lymphoid malignancies and minimal residual disease detection
US9499865B2 (en) 2011-12-13 2016-11-22 Adaptive Biotechnologies Corp. Detection and measurement of tissue-infiltrating lymphocytes
EP3372694A1 (de) 2012-03-05 2018-09-12 Adaptive Biotechnologies Corporation Festlegung von gepaarten immunrezeptorketten aus frequenzabgestimmten untereinheiten
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
HUE029357T2 (en) 2012-05-08 2017-02-28 Adaptive Biotechnologies Corp Preparations and devices for measuring and calibrating amplification distortion in multiplex PCR reactions
EP2861760B1 (de) 2012-06-15 2020-01-01 The Board of Regents of The University of Texas System Sequenzierung von mehreren transkripten aus einer einzelnen zelle mit hohem durchsatz
EP3330384B1 (de) 2012-10-01 2019-09-25 Adaptive Biotechnologies Corporation Immunkompetenzbeurteilung durch adaptive immunrezeptordiversität und klonalitätscharakterisierung
WO2015160439A2 (en) 2014-04-17 2015-10-22 Adaptive Biotechnologies Corporation Quantification of adaptive immune cell genomes in a complex mixture of cells
US9708657B2 (en) 2013-07-01 2017-07-18 Adaptive Biotechnologies Corp. Method for generating clonotype profiles using sequence tags
WO2015134787A2 (en) 2014-03-05 2015-09-11 Adaptive Biotechnologies Corporation Methods using randomer-containing synthetic molecules
CA3124228C (en) 2014-03-21 2024-05-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
US10066265B2 (en) 2014-04-01 2018-09-04 Adaptive Biotechnologies Corp. Determining antigen-specific t-cells
US11390921B2 (en) 2014-04-01 2022-07-19 Adaptive Biotechnologies Corporation Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs)
CA2966201A1 (en) 2014-10-29 2016-05-06 Adaptive Biotechnologies Corp. Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from many samples
US10246701B2 (en) 2014-11-14 2019-04-02 Adaptive Biotechnologies Corp. Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture
AU2015353581A1 (en) 2014-11-25 2017-06-15 Adaptive Biotechnologies Corporation Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing
CA2976580A1 (en) 2015-02-24 2016-09-01 Adaptive Biotechnologies Corp. Methods for diagnosing infectious disease and determining hla status using immune repertoire sequencing
CA2979702A1 (en) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
US10513733B2 (en) 2015-03-23 2019-12-24 Board Of Regents, The University Of Texas System High throughout sequencing of paired VH and VL transcripts from B cells secreting antigen-specific antibodies
EP3277294B1 (de) 2015-04-01 2024-05-15 Adaptive Biotechnologies Corp. Verfahren zur identifizierung von menschlichen kompatiblen t-zell-rezeptoren spezifisch für ein antigen-ziel
US10428325B1 (en) 2016-09-21 2019-10-01 Adaptive Biotechnologies Corporation Identification of antigen-specific B cell receptors
WO2019084538A1 (en) 2017-10-27 2019-05-02 Board Of Regents, The University Of Texas System TUMOR SPECIFIC ANTIBODIES, T CELL RECEPTORS AND METHODS OF IDENTIFICATION THEREOF
US11254980B1 (en) 2017-11-29 2022-02-22 Adaptive Biotechnologies Corporation Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2006878A1 (en) * 1988-12-29 1990-06-29 John D. Rodwell Molecular recognition units
US6291158B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
DE19739685A1 (de) * 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
EP1355946B1 (de) * 2001-01-15 2006-11-02 Keryos Spa Dns-vakzine von hypervariablen vh-cdr3 idiotypischen determinanten
GB0309126D0 (en) * 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies

Also Published As

Publication number Publication date
ES2236605T3 (es) 2005-07-16
DE60202877T2 (de) 2006-04-13
EP1415002B1 (de) 2005-02-02
CA2471570A1 (en) 2003-06-26
PT1415002E (pt) 2005-05-31
EP1415002A2 (de) 2004-05-06
US20060233812A1 (en) 2006-10-19
AU2002352394A1 (en) 2003-06-30
DE60202877D1 (de) 2005-03-10
WO2003052416A3 (en) 2003-10-16
GB0130267D0 (en) 2002-02-06
WO2003052416A2 (en) 2003-06-26

Similar Documents

Publication Publication Date Title
ATE288502T1 (de) Gezieltes antikörper-verfahren
CY1108765T1 (el) ΑΓΩΓΗ ME ΑΝΤΙΣΩΜΑΤΑ ANTI-ErbB2
DK1355930T3 (da) Fremgangsmåde til identifikation, isolering og fremstilling af antigener mod et specifikt patogen
CY1113243T1 (el) Μεθοδοι θεραπειας με χρηση αντισωματων cτlα-4
TW200528117A (en) Methods and reagents for the treatment of proliferative diseases
ATE406912T1 (de) Immunisierung gegen chlamydia tracheomatis
BR0111125A (pt) Moléculas de ácido nucléico de nrg-2, polipeptìdeos, e métodos diagnóstico e terapêuticos
WO2003039462A3 (en) B-cell lymphoma specific antigen for use in diagnosis and treatment of b-cell malignancies
CY1105389T1 (el) Hpv-e7 ως αγωγη εναντι του ιου θηλωματων ανθρωπου
CY1107146T1 (el) Μεθοδοι για προληψη και θεραπεια ασθενειας alzheimer (ad)
CR8698A (es) Anticuerpos monoclonales al factor de crecimiento de hepatocito
ATE521361T1 (de) Verfahren zur behandlung von gebärmutterhalskrebs
ID30223A (id) Penggunaan antibodi untuk vaksinasi melawan kanker
DK1471936T3 (da) HIV-Vaccine og fremgangsmåde til anvendelse
DE60218473D1 (de) Verfahren zur herstellung polyvalenter bakteriophagenpräparationen zur behandlung bakterieller infektionen
ATE425187T1 (de) Materialien und methoden zur behandlung von hepatitis c
DE60222296D1 (de) Impfstoff von umhüllten viren und verfahren zu seiner herstellung
ATE381942T1 (de) Mittel zur behandlung von infektionen mit leishmanien
DE60327768D1 (de) Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease
WO2002072013A3 (en) Method of treating malignancies through induction of blood immune responses
EP1667634A4 (de) Anthrax-vakzine
DK1146889T3 (da) Identifikation af specifikke differentielt udtrykte mycobakterielle antigener og medicinsk anvendelse af Mycobakteriumproteinerne Rv0068 og Rv3407
DE60233936D1 (de) Therapeutische Zusammenseztungen zur Toleranzinduktion
EA200100701A1 (ru) Белки наружной поверхности, их гены и их применение
BR0318688A (pt) polipeptìdeo para o diagnóstico e terapia de leishmania

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1415002

Country of ref document: EP